Interim FDG-PET Imaging in Lymphoma

被引:24
作者
Gallamini, Andrea [1 ]
Zwarthoed, Colette [2 ]
机构
[1] A Lacassagne Canc Ctr, Res Innovat & Stat Dept, Nice, France
[2] A Lacassagne Canc Ctr, Nucl Med Dept, Nice, France
关键词
POSITRON-EMISSION-TOMOGRAPHY; B-CELL LYMPHOMA; STAGE HODGKINS LYMPHOMA; PROGRESSION-FREE SURVIVAL; PERIPHERAL T-CELL; EARLY F-18-FDG PET; RESPONSE ASSESSMENT; PROGNOSTIC VALUE; OPEN-LABEL; INTERPRETATION CRITERIA;
D O I
10.1053/j.semnuclmed.2017.09.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma. A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemotherapy treatment, but an increased number of reports have recently been published focusing on the role of iPET in relapsed or refractory lymphoma to predict treatment outcome. Varying patterns of FDG uptake was observed across various lymphoma entities; hence, interpretation of FDG-PET scans should be in the context of the tumor architecture and the prevalence of cellular population, in particular, neoplastic vs non-neoplastic inflammatory cells present in tissue microenvironment. In the second part of the article, the authors reviewed the iPET response adapted clinical trials and the clinical benefits of this strategy compared to standard non PET adapted therapy. In particular, the authors extrapolated the reproducibility of FDG-PET image interpretation and the feasibility of a timely treatment adaptation based on FDG-PET results in daily clinical practice. This is essential for the reader, as the iPET-adapted strategy has become the standard of care in both early- and advanced-stage Hodgkin lymphoma, and, in the future, probably this strategy will be expanded to primary mediastinal B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 50 条
  • [31] Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis
    Adams, Hugo J. A.
    Kwee, Thomas C.
    EUROPEAN JOURNAL OF RADIOLOGY, 2016, 85 (11) : 1963 - 1970
  • [32] Unproven Clinical Value of Interim FDG-PET in Aggressive Non-Hodgkin Lymphoma
    Adams, Hugo J. A.
    Kwee, Thomas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3271 - +
  • [33] Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients
    Atkinson, Wendy
    Catana, Ciprian
    Abramson, Jeremy S.
    Arabasz, Grae
    McDermott, Shanaugh
    Catalano, Onofrio
    Muse, Victorine
    Blake, Michael A.
    Barnes, Jeffrey
    Shelly, Martin
    Hochberg, Ephraim
    Rosen, Bruce R.
    Guimaraes, Alexander R.
    ABDOMINAL RADIOLOGY, 2016, 41 (07) : 1338 - 1348
  • [34] Update on FDG-PET in pediatric lymphoma
    Kurch, Lars
    Kluge, Regine
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 68 (01) : 58 - 69
  • [35] FDG-PET scans in patients with lymphoma
    Elstrom R.L.
    Leonard J.P.
    Current Hematologic Malignancy Reports, 2008, 3 (4) : 197 - 203
  • [36] Interest of FDG-PET in the Management of Mantle Cell Lymphoma
    Bailly, Clement
    Carlier, Thomas
    Touzeau, Cyrille
    Arlicot, Nicolas
    Kraeber-Bodere, Francoise
    Le Gouill, Steven
    Bodet-Milin, Caroline
    FRONTIERS IN MEDICINE, 2019, 6
  • [37] Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
    Hutchings, M
    Mikhaeel, NG
    Fields, PA
    Nunan, T
    Timothy, AR
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1160 - 1168
  • [38] The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well established
    Adams, H. J. A.
    Kwee, T. C.
    ANNALS OF ONCOLOGY, 2018, 29 (02) : 510 - 512
  • [39] Predicting outcomes after a positive interim FDG-PET scan in advanced Hodgkin's lymphoma
    Crump, Michael
    LANCET ONCOLOGY, 2017, 18 (04) : 416 - 418
  • [40] FDG-PET for Early Response Assessment in Lymphomas PART 1: Hodgkin Lymphoma
    Cheson, Bruce D.
    Kostakoglu, Lale
    ONCOLOGY-NEW YORK, 2017, 31 (01): : 45 - 49